IDiyas

For the Inventor, By the Inventor

Heitersheim, Germany

Joachim Nozulak

USPTO Granted Patents = 12 

 

Average Co-Inventor Count = 2.9

ph-index = 3

Forward Citations = 51(Granted Patents)


Location History:

  • Hartheim, DE (1987)
  • Heitersheim, DE (1993 - 2017)

Company Filing History:

goldMedal10 out of 3,923 
 
Novartis Ag
 patents
silverMedal2 out of 1,603 
 
Sandoz Gmbh
 patents

Years Active: 1987-2017

Loading Chart...
Loading Chart...
12 patents (USPTO):
1. 9670193 - Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease (2017-06-06),
2. 9067881 - 4-tolyl-ethynyl-octahydro-indole-1-ester derivatives (2015-06-30),
3. 8513268 - 1H-quinazoline-2,4-diones processes for their production, pharmaceutical compositions, and treatment for epilepsy (2013-08-20),
4. 8299085 - Quinazoline derivatives (2012-10-30),
5. 8012988 - N-(2,4-dioxo-6-(tetrahydrofuran-2-yl)-7-(trifluoromethyl)-1,4-dihydro-2H-quinazolin-3-yl)methanesulfonamide (2011-09-06),
6. 7786155 - Organic compounds (2010-08-31),
7. 7696379 - Acetylene derivatives (2010-04-13),
8. 7655666 - Substituted 1H-quinazoline-2,4-diones useful as AMPA receptor ligands (2010-02-02),
9. 7012085 - 1,3 disubstituted pyrrolidines as α-2-adrenoceptor antagonists (2006-03-14),
10. 6780861 - Azabicyclic carbamates and their use as &agr;-7 nicotinic acetylcholine receptor agonists (2004-08-24),
11. 5190941 - Use of naphthoxazines for the treatment of conditions associated with (1993-03-02),
12. 4656167 - Naphthoxazines and their use as psychostimulating and antidepressant (1987-04-07),

Title: Innovations and Contributions of Inventor Joachim Nozulak

Introduction

Joachim Nozulak is a prominent inventor based in Heitersheim, Germany. He has made significant contributions to the field of pharmaceuticals, holding a total of 12 patents. His work focuses on developing novel compounds that have potential therapeutic applications.

Latest Patents

Among his latest patents, Nozulak has developed trifluoromethyl-oxadiazole derivatives and their use in the treatment of diseases. This invention relates to novel trifluoromethyl-oxadiazole derivatives of a specific formula, along with their pharmaceutically acceptable salts. These compounds are particularly aimed at treating neurodegeneration, muscle atrophy, or diabetes/metabolic syndrome through the inhibition of HDAC4. Another notable patent involves 4-tolyl-ethynyl-octahydro-indole-1-ester derivatives. This invention encompasses compounds of a defined formula, which can be utilized in free form or as salts, and highlights their preparation and use as medicaments.

Career Highlights

Throughout his career, Joachim Nozulak has worked with renowned companies such as Novartis AG and Sandoz GmbH. His experience in these organizations has allowed him to contribute to the advancement of pharmaceutical innovations.

Collaborations

Nozulak has collaborated with notable colleagues, including David Orain and Hans Allgeier. These partnerships have further enriched his research and development efforts.

Conclusion

Joachim Nozulak's innovative work in the pharmaceutical industry has led to the development of important compounds with potential medical applications. His contributions continue to impact the field positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…